Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15805928 | 0.83 | PDPK1 (0.55) | CLK4PDPK1CYP2A6GRM5LOXL2 | |
| SCHEMBL15805858 | 0.82 | PDPK1 (0.72) | PDPK1CYP2A6LOXL2KAT6A | |
| SCHEMBL2225287 | 0.79 | PDPK1 (0.57) | PDPK1CYP2A6LOXL2 | |
| SCHEMBL16159287 | 0.78 | PDPK1 (0.67) | PDPK1CYP2A6LOXL2KAT6A | |
| SCHEMBL5107105 | 0.78 | GRM5 (0.62) | CLK4PDPK1GRM5CYP1A2CYP3A4 | |
| SCHEMBL16122987 | 0.77 | PDPK1 (0.47) | PDPK1CYP2A6GRM5LOXL2KAT6A | |
| Hydrochloric Acid SCHEMBL5107032 | 0.77 | GRM5 (0.61) | CLK4PDPK1GRM5CYP1A2CYP3A4 | |
| SCHEMBL5215750 | 0.77 | GRM5 (0.63) | CLK4PDPK1CYP2A6GRM5NOTUM | |
| SCHEMBL3389168 | 0.77 | CYP2A6 (0.49) | PDPK1CYP2A6LOXL2 | |
| SCHEMBL21778063 | 0.76 | PDPK1 (0.54) | PDPK1CYP2A6LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6345724-A | — | — | None | — | — | JP | disclosed |
| JP-11100376-A | — | — | None | — | — | JP | disclosed |
| JP-11060552-A | — | — | None | — | — | JP | disclosed |
| JP-10139770-A | — | — | None | — | — | JP | disclosed |
| EP-1956015-B2 | Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same | TEIJIN LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| CN-108347943-A | HEPATITIS B CORE PROTEIN MODULATORS | 组装生物科学股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-106892879-A | A kind of synthetic method of gout suppressant Febustat | 青岛黄海制药有限责任公司 | 2017-06-27 | — | — | CN | disclosed |
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-105001302-A | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-10-28 | — | — | CN | disclosed |
| CN-102741270-B | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-07-22 | — | — | CN | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| JP-H11100376-A | PRODUCTION OF 2,3-DIHYDROBENZO(B)FURAN DERIVATIVE AND MEDICINE | TEIJIN LTD | 1999-04-13 | — | — | JP | disclosed |
| JP-H1160552-A | PRODUCTION OF THIOBENZAMIDE DERIVATIVE | TEIJIN LTD | 1999-03-02 | — | — | JP | disclosed |
| JP-H10139770-A | PRODUCTION OF 2-(3-CYANOPHENYL)THIAZOLE DERIVATIVE | TEIJIN LTD | 1998-05-26 | — | — | JP | disclosed |
| JP-H06345724-A | CYANO COMPOUND AND ITS PRODUCTION | TEIJIN LTD | 1994-12-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CLK4 1067/4885PDPK1 93/4885CYP2A6 1170/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CLK4 337/4885PDPK1 69/4885CYP2A6 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.